Workflow
Revolution Medicines to Participate in the Guggenheim Securities SMID Cap Biotech Conference

Core Insights - Revolution Medicines, Inc. is a clinical-stage oncology company focused on developing targeted therapies for RAS-addicted cancers [3] - The company will participate in the Guggenheim Securities SMID Cap Biotech Conference on February 5, 2025, with CEO Mark A. Goldsmith as a speaker [1] Company Overview - Revolution Medicines is developing RAS(ON) inhibitors aimed at suppressing various oncogenic variants of RAS proteins [3] - The R&D pipeline includes daraxonrasib (RMC-6236), elironrasib (RMC-6291), and zoldonrasib (RMC-9805), which are currently in clinical development [3] - Additional pipeline opportunities focus on RAS(ON) mutant-selective inhibitors such as RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C) [3]